

Guidelines for Transparency in the Relationship Between Corporate Activities and Medical Institutions

We have established the Kissei Code of Conduct and pursue business activities with the aim of contributing to the health of people around the world and to the advancement of medical care through the development and provision of highly original pharmaceuticals and outstanding products that contribute to health through diet. As a member of the life sciences industry with significant involvement in the lives and health of patients and the people of Japan and that exists under the universal healthcare insurance system, it is crucial that Japan's pharmaceutical industry, more than any other industry, demonstrate transparency in its activities. In our aim to be an R&D-oriented pharmaceutical company that will earn even greater trust from society, we establish the Guidelines for Transparency in the Relationship Between Corporate Activities and Medical Institutions.

1. Our Approach to Transparency

We strive to ensure the transparency of the relationship between all our corporate activities and medical institutions, etc. in accordance with both the letter and the spirit of relevant guidelines, including those established by the Japan Pharmaceutical Manufacturers Association (JPMA), including the JPMA Charter of Corporate Behavior, JPMA Compliance Program/Guideline, and JPMA Code of Practice.

2. Method of Disclosure

Information is disclosed on the Company website.

3. Timing of Disclosure

Disclosures are made no later than one year after the end of each fiscal year.

4. Scope of Disclosure

A Research and development expenses, etc.

Research and development expenses, etc. include expenses required for research, surveillance, etc. conducted based on official regulations such as the ministerial ordinances on good clinical practice, good vigilance practice, and good post-marketing study practice under the Clinical Trials Act and the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, and various guidelines. Funds provided are disclosed as follows along with the total annual amount of each item.

● Specified clinical trial expenses (Note 1)	Name, etc. of relevant institution, etc. (Note 2)	: XX yen for XX cases
● Expenses for research based on ethical guidelines (Note 3)	Name of relevant institution, etc. (Note 4)	: XX yen for XX cases
● Nonclinical research expenses (Note 5)	Name of relevant institution, etc. (Note 4)	
● Clinical trial expenses	Name of relevant institution, etc. (Note 4)	: XX yen for XX cases
● Post-marketing clinical study expenses	Name of relevant institution, etc. (Note 4)	: XX yen for XX cases
● Adverse drug reaction and infection case reporting expenses	Name of relevant institution, etc. (Note 4)	: XX yen for XX cases
● Post-marketing surveillance expenses	Name of relevant institution, etc. (Note 4)	: XX yen for XX cases
● Other expenses	Annual total	

- (Note 1) “Specified clinical trial expenses” refers to expenses paid under contracts for specified clinical trials as defined in the Clinical Trials Act.
- (Note 2) “Clinical trial ID No.,” “Recipient of funds,” “Name of medical institution conducting trial,” “Name of physician responsible for trial,” etc. will be disclosed.
- (Note 3) “Ethical guidelines” in “Expenses for research based on ethical guidelines” refers to “Ethical Guidelines for Medical and Biological Research Involving Human Subjects” (Medical and Biological Research Guidelines)
- (Note 4) For “Name of relevant institution, etc.,” “Name of relevant institution,” “Name of organization within relevant institution,” and “Affiliation, position, and name of individual” will be disclosed based on the contract.
- (Note 5) “Nonclinical research expenses” refers to costs incurred for research other than specified clinical trials, research conducted under ethical guidelines, clinical trials, or post-marketing surveillance. This includes so-called “basic research” and “pharmaceutical formulation studies.”

B Academic Research Grants

Scholarship donations and general donations made for such purposes as promoting academic research and supporting research, as well as donations and co-sponsorship expenses for academic conferences, etc. to support the costs of holding academic conferences

“Co-sponsorship expenses, etc. for academic conferences, etc.” include seminar co-hosting expenses, ad placement fees, and exhibition fees incidental to the holding of meetings.

Funds provided are disclosed as follows along with the total annual amount of each item.

- Scholarship donations AA Dept., BB University : XX yen for XX donations
- General donations AA University : XX yen for XX donations
(or BB Foundation)
- Donations for academic conference, etc. Nth Meeting of the AA : XX yen
Society (BB Regional Meeting /CC Research Group)
- Co-sponsorship expenses, etc. Nth Meeting of the AA : XX yen
for academic conferences, etc. Society (BB Regional Meeting /CC Research Group)

(*This item also includes information subject to mandatory disclosure under the Clinical Trials Act)

C Fees for Writing Manuscripts, Etc.

Expenses paid to provide scientific information, etc. on the medical and pharmaceutical sciences, including the Company’s pharmaceuticals, or as consideration for lectures and writing/supervision of manuscripts related to research and development, or for consulting and other outsourced services Funds provided are disclosed as follows along with the total annual amount of each item.

- Honoraria for speakers Professor (Department Head) AA, : XX yen for XX projects
BB Dept., CC University
(DD Hospital)
- Fees for writing/supervising manuscripts Professor (Department Head) AA, : XX yen for XX projects
BB Dept., CC University
(DD Hospital)
- Consulting and other outsourcing expenses Professor (Department Head) AA, : XX yen for XX projects
BB Dept., CC University
(DD Hospital)

(*This item also includes information subject to mandatory disclosure under the Clinical Trials Act)

D Expenses related to information provision
Expenses for seminars, briefings, etc., to provide healthcare professionals with information on the Company's pharmaceuticals and on medicine and pharmacology

- Expenses for seminars and other meetings Total number of seminars, etc. and total amount for the year
- Expenses for briefings Total number of briefings and total amount for the year
- Expenses for provision of medical and pharmaceutical literature, etc. Annual total

E Other expenses
Expenses for hospitality, etc. provided as a social courtesy

- Expenses for hospitality, etc. Annual total

5. Timing of application
These guidelines apply to payments in and after FY2023.

Established December 1, 2011
Revised September 12, 2019
Revised April 1, 2024